Nucleotide sequence of the normal AML1, MTG16a transcripts and of the AML1-MTG16 fusion transcript as characterized in both t(16;21) patients. AML1 sequences appear in lower case letters and MTG16 in upper case letters.
Figure 3
Nucleotide sequence of the normal AML1, MTG16a transcripts and of the AML1-MTG16 fusion transcript as characterized in both t(16;21) patients. AML1 sequences appear in lower case letters and MTG16 in upper case letters.
cases, it seems premature to define the hematologic characteristics of the leukemias with t(16;21) and MTG16-AML1 fusion. They are mainly therapy-related leukemias, with negativity for lymphoid markers, and cytologic features resembling the usual AML-M2 more than those of t(8;21) leukemia. In addition, the study of more cases should help to establish the prognostic value of the translocation and its associated fusion gene on the one hand, and to analyze the functional consequences of the molecular abnormality on the other hand. of an abnormal chromosome containing material from the long arm of chromosome 11 were observed. Diagnostic bone marrow cells were analyzed by interphase FISH with probes to the centromere of chromsome 11 and to the MLL gene (D11Z1 and 11q23, Appligene-Oncor, France). Three signals for MLL and two for 11 centromere were seen. The BCR/ABL (S-FISH Translocation DNA Probe, Appligene-Oncor, France) and TEL/AML1 (LSI, Vysis, UK) probes revealed no fusion signals, single signals for ABL (9q34) and TEL (12p13) (exons 1-4) and three signals for AML1 (21q22). These findings were seen in 88% of cells. Molecular analysis by Southern blotting showed no rearrangement of the MLL gene.
The abnormalities suspected from G-banding ( Figure 1 ) and interphase FISH were confirmed on metaphases using whole chromosome paints (wcp) (Star FISH chromosome paints, Cambio, UK) for each of the 24 chromosomes, centromeric probes for chromosomes 7, 9, 10, 11, 12 and 20 (Appligene-Oncor) and cosmid probes to exons 5/6 and 8 of ETV6 (184C4 and 148B6, respectively). The karyotype was defined on a single metaphase from the slide used for MLL interphase studies. Thirteen sequential hybridizations were performed on this cell by the modification of a previously described technique Our study has shown that the combination of interphase FISH and sequential metaphase FISH on the same slide, can successfully be used to define the size of a malignant cell population and the karyotype in cases with limited material. Interphase FISH showed that the majority of cells belonged to the malignant clone, although there were relatively few analyzable abnormal metaphases. 4 Metaphase FISH was remarkable in that it highlighted the involvement of over half the chromosomes in complex rearrangements. Only chromosomes X, Y, 4, 5, 13, 14, 15, 16 and 18 appeared to be normal. The MLL gene occurred on a normal chromosome 11 and on the duplicated marker seen by G-banding which proved to be a der(7), composed of chromosome 7 to just below the centromere, 7q replaced by part of 11q and chromosome 3 material translocated at its end. Material from chromosome Metaphase defined by (a) sequential FISH with whole chromosome paints; (b) the DAPI image converted to black and white, captured with Smart Capture Software, Vyvis. 45,XY,der(1)t(1;17)(p;p),der(3)t(3;7)(q;?),inv(6)ins(6;7)(q;?q),der(7)t(7;11;3)(q;q;?),der(9)t(9;17) (q;q),der(10)t(10;1)(q;p),der(11)t(11;7)(q;?),der(12)t(2;7;12)(?;q;p),dic(12;20)(p;?),der(19)t(19;7)(q;q),+21,?dic(21;22)(p;p),der(22)t(3;22)(q;p). The karyotype describes chromosomes (as defined by FISH) from pter to qter. Arm designations are tentative for some chromosomes.
7 was also translocated to 3q, while fragments of 7 were attached to a der(11) just below the centromere and inserted into 6q. Characteristic dark bands, of 7q origin, were translocated to a chromosome 19 and to a der(12) telomeric to ETV6, which terminated in material from chromosome 2. Loss of ABL occurred from a der(9)t(9;17) and loss of ETV6 from a dic(12;20) including the long arm of chromosome 12. There were three copies of chromosome 21, one of which formed a dicentric with chromosome 22. The other 22 was also involved in a pericentric rearrangement but with chromosome 3 material. Only one centromere appeared to be lost from the karyotype -that of one chromosome 7. Overall there appeared to be gain of material from chromosomes 2, 3, 11, 17, 21 and loss from chromosomes 1, 9, 10, 12, 19 and 20. Pericentric rearrangements have been described in ALL but their multiplicity in our case appears to be unique. The derived chromosomes 7, 11, 12, 19 and 22 and the dicentrics (12;20) and (21;22) all appeared to involve at least one near centromeric break. The potential importance of such rearrangements in hematological malignancies has been noted. 5 Chromosome 7 material had been translocated or inserted into six different places in the karyotype. Except for the probable long arm provenance of the material on the der(12) and der(19) it was impossible to define its p or q origin. The chromosome 3 breakpoint on the der(3)t(3;7) seemed to be in band q27 where the BCL-6 gene is located, which has been described to be involved with chromosome 7, t(3;7)(q27;p12), in B cell diffuse large cell lymphoma. 6 At the Leukaemia Research Fund/UK Cancer Cytogenetics Group Karyotype Database in ALL there is a case which involves an insertion of chromosome 3 into the short arm of chromosome 7 (unpublished data). Fragmentation of chromosome 7 and its complex involvement with translocation partners including chromosomes 12 and 19 have been described in myeloid disorders. 7, 8 This patient is only 20 months into a first complete remission, so there is as yet no indication of the prognostic implications of his kary-otype. In myeloid disorders, loss of chromosome 7 material has been associated with a poor prognosis, as has a complex karyotype. [8] [9] [10] In lymphoid disorders, loss of chromosome 7 does not appear to indicate a poorer outcome in adult patients with ALL who do not have a Philadelphia chromosome. 11 The significance of a complex karyotype is less clear in ALL. However, with the new techniques available, 12 including this sequential FISH approach, previously unidentifiable and even unsuspected abnormalities are being defined in many hematological malignancies. It seems likely that some of these cytogenetic changes may have no effect on prognosis.
whether this holds also true for t(12;21)-positive ALL and whether we are able to discriminate between children, who are likely to be cured from those, who are at risk for a relapse.
In the present study, we selected 57 children with B cell precursor (BCP) ALL according to the availability of bone marrow samples at diagnosis, during the course of therapy and at relapse. Eight patients had high risk leukemia according to BFM criteria (prednisone poor response, t(4;11), or t(9;22)). None of the prednisone poor responders had a t(12;21)-positive leukemia and they were therefore excluded from further analysis. The remaining 49 children with non-high risk BCP ALL were treated in Austria according to current BFM protocols 4 (ALL-BFM 90: n = 43, ALL-BFM 95: n = 6) between January 1992 and November 1996. Age at diagnosis ranged from 3 months to 14 years (median 5 years). Clinical characteristics of the patients did not deviate from those of the additional 189 children with non-high risk BCP-ALL enrolled in the ALL-BFM studies in Austria during the study period. To increase the number of relapses from t(12;21)-positive leukemias two additional patients with a late relapse of their t(12;21)-positive ALL, one isolated in the ovary after 4.1 years and the other in the bone marrow after 4.5 years, from whom follow-up samples for MRD analysis were available, have been included.
After the identification of leukemia clone-specific antigen receptor
